Shares of Freenome (NASDAQ:FRNM – Get Free Report) reached a new 52-week low during mid-day trading on Friday. The company traded as low as $9.90 and last traded at $9.9640, with a volume of 280,281 shares changing hands. The stock had previously closed at $10.47.
Wall Street Analyst Weigh In
A number of brokerages recently commented on FRNM. Leerink Partners assumed coverage on Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 price objective on the stock. TD Cowen initiated coverage on Freenome in a research note on Tuesday, August 18th. They issued a “buy” rating and a $17.00 target price for the company. Wall Street Zen upgraded Freenome to a “sell” rating in a report on Saturday, September 26th. Guggenheim began coverage on Freenome in a report on Thursday, August 20th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Jefferies Financial Group began coverage on shares of Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $18.00.
Read Our Latest Research Report on FRNM
Freenome Stock Performance
The company has a fifty day moving average of $14.52. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -169.47 and a beta of 0.60.
About Freenome
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at an early stage. Its platform combines artificial intelligence with multiomics, including genomic, epigenomic and proteomic signals found in blood, to identify patterns associated with cancer.
The company has focused its research and clinical development efforts on screening for colorectal cancer and other common cancers. Freenome’s products are intended to support noninvasive screening and may complement or provide an alternative to certain conventional screening methods, subject to regulatory review and approval.
Founded in 2014, Freenome is headquartered in South San Francisco, California.
Featured Articles
- Five stocks we like better than Freenome
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
- Arista Networks Cashes In on the AI Infrastructure Buildout
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
